These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24292367)

  • 1. Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.
    Liu YM; Cheng YJ; Li YL; Liu CE; Hsu WH
    Lung; 2014 Feb; 192(1):205-10. PubMed ID: 24292367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral hepatitis prevalence in patients with active and latent tuberculosis.
    Nooredinvand HA; Connell DW; Asgheddi M; Abdullah M; O'Donoghue M; Campbell L; Wickremasinghe MI; Lalvani A; Kon OM; Khan SA
    World J Gastroenterol; 2015 Aug; 21(29):8920-6. PubMed ID: 26269682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.
    Chen L; Bao D; Gu L; Gu Y; Zhou L; Gao Z; Huang Y
    BMC Infect Dis; 2018 Jul; 18(1):295. PubMed ID: 29970037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
    Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
    Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of chronic viral hepatitis on tuberculosis treatment interruption.
    Chua AP; Lim LK; Gan SH; Chee CB; Wang YT
    Int J Tuberc Lung Dis; 2018 Dec; 22(12):1486-1494. PubMed ID: 30606322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.
    Kim WS; Lee SS; Lee CM; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ; Hong JW; You HS; Cho HC
    BMC Infect Dis; 2016 Feb; 16():50. PubMed ID: 26833347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.
    Ungo JR; Jones D; Ashkin D; Hollender ES; Bernstein D; Albanese AP; Pitchenik AE
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1871-6. PubMed ID: 9620920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity.
    Sarda P; Sharma SK; Mohan A; Makharia G; Jayaswal A; Pandey RM; Singh S
    Indian J Med Res; 2009 Jan; 129(1):64-7. PubMed ID: 19287059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.
    Baghaei P; Tabarsi P; Chitsaz E; Saleh M; Marjani M; Shemirani S; Pooramiri MV; Kazempour M; Farnia P; Fahimi F; Mansouri D; Masjedi M
    Am J Ther; 2010; 17(1):17-22. PubMed ID: 19535968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
    Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
    Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis.
    Zhu CH; Zhao MZ; Chen G; Qi JY; Song JX; Ning Q; Xu D
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):105-109. PubMed ID: 28224437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.
    Trigo C; do Brasil PE; Costa MJ; de Castro L
    J Viral Hepat; 2016 Dec; 23(12):1027-1035. PubMed ID: 27624908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study.
    Song JH; Yoon SY; Park TY; Heo EY; Kim DK; Chung HS; Lee JK
    Respir Res; 2019 Dec; 20(1):283. PubMed ID: 31842883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy.
    Kwon YS; Koh WJ; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2007 Mar; 131(3):803-808. PubMed ID: 17356096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: A systematic review and meta-analysis.
    Chou C; Veracruz N; Chitnis AS; Wong RJ
    J Viral Hepat; 2022 Dec; 29(12):1107-1114. PubMed ID: 36138556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced hepatotoxicity and association with slow acetylation variants NAT2*5 and NAT2*6 in Cameroonian patients with tuberculosis and HIV co-infection.
    Cho FN; Achidi EA; Enoh JE; Pallerla SR; Linh LTK; Tong HV; Kamgno J; Penlap VB; Adegnika AA; Lekana-Douki JB; Bouyou-Akotet MK; Kahunu GM; Lutete GT; Bates M; Tembo J; Elton L; McHugh TD; Grobusch MP; Zumla A; Ntoumi F; Velavan TP
    BMC Infect Dis; 2024 Jul; 24(1):759. PubMed ID: 39085767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus.
    Mo P; Zhu Q; Teter C; Yang R; Deng L; Yan Y; Chen J; Zeng J; Gui XE
    Int J Infect Dis; 2014 Nov; 28():95-100. PubMed ID: 25218771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.